Biogen's Alzheimer's drug could cost Medicare billions of dollars a year, report finds

Biogen said it is charging $56,000 for an annual course of the new treatment, higher than the $10,000 to $25,000 price some Wall Street analysts were expecting.

from Health and Science https://ift.tt/3v8WrtT
https://ift.tt/eA8V8J
https://ift.tt/2zIUzyH